



WCLC 2021 and ESMO 2021 in an Hour BTOG Webinar

Monday 27th September 2021 17:30-18:30 BST

Approved for 1 category 1 (external) CPD credit (code 137383)

From the Federation of the Royal Colleges of Physicians of the United Kingdom

Chair: Dr Tom Newsom-Davis – BTOG Steering Committee Vice-Chair

BTOG Steering Committee members will present an update on relevant data/research presented at WCLC 2021 and ESMO 2021 on the topics below.

| | | |
|-------|--|------------------|
| 17:30 | Welcome | Tom Newsom-Davis |
| 17:30 | Radiotherapy | David Gilligan |
| 17:40 | Q&A | Tom Newsom-Davis |
| 17:45 | Early/Advanced NSCLC TKI / Small Cell Lung Cancer | Samreen Ahmed |
| 18:00 | Q&A | Tom Newsom-Davis |
| 18:05 | Early/Advanced NSCLC Immunotherapy / Mesothelioma / Thymic | Riyaz Shah |
| 18:20 | Q&A | Tom Newsom-Davis |
| 18:30 | Close | Tom Newsom-Davis |

Sponsors have provided sponsorship towards this independent webinar programme.



MSD



**Boehringer
Ingelheim**

Lilly



Bristol Myers Squibb™

Declarations

1. BTOG confirms that all speakers will introduce themselves and will include as their 1st slide a declaration of conflict of interests and this will be visible to attendees.
2. BTOG confirms there will be a clear view of each speaker's slides. Each speaker will talk to the slides and their voice will accompany the slide discussion (where applicable).
3. BTOG confirms that participants viewing the educational presentations live will be able to submit questions and comments via live webinar chat.
4. BTOG confirms that if RCP approves this live webinar BTOG will provide access via BTOG's online resources and note that CPD will apply to the archived version for four weeks after the event date – we will ensure participants viewing the full archived version will be awarded the appropriate CPD and be issued a certificate of attendance.

Biographies

Professor Samreen Ahmed - I have been a Consultant in Medical Oncology since 2006 and qualified in 1994 at the Royal Free Hospital School of Medicine London. I have a research degree (MD) through Nottingham University and undertook Oncology training in Western Park Hospital (Sheffield), Nottingham City Hospital and the Leicester Royal Infirmary. I am a Fellow of the Royal College of Physicians. I am Training Programme Director for Medical Oncology. I am the research Lead for both breast and lung cancer in the East Midlands Cancer Network. I work with the National Cancer Research Network as a trialist.

David Gilligan is a Consultant Clinical Oncologist at Addenbrooke's and Papworth Hospitals in Cambridge. He is the Clinical Lead for Acute Oncology at Addenbrooke's. He trained in pre-clinical medicine at the University of Edinburgh and clinical medicine at the University of Cambridge. His specialist training in Oncology was at the Christie Hospital, Manchester; Royal Marsden Hospital, and University College Hospitals, London. His main clinical interests are in all aspects of Thoracic Oncology and Upper GI tract cancer and is an enthusiastic participator in clinical trials. He has been a member of the NCRI Lung Cancer Studies Group. He is currently a member of UK Department of Health Lung Cancer and Mesothelioma Advisory Group, Specialist Advisor to Cancer Backup and CancerHelp UK and a Trustee of the Roy Castle Lung Cancer Foundation.

Dr Tom Newsom-Davis is a consultant in medical oncology at Chelsea and Westminster Hospital, London, where he specialises in thoracic malignancies. He has been a member of the BTOG Steering Committee for the past 2 years, and until recently was part of the National Cancer Research Institute Lung Group and led the RM Partners Cancer Vanguard lung pathway. Dr Newsom-Davis is actively involved in clinical research and has presented his work at a number of national and international meetings. He has been an invited lecturer for various organisations including BTOG, the Royal College of Physicians, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians. In 2015, his work was awarded the Macmillan Innovation Excellence Award.

Dr Riyaz Shah qualified from Guy's and St Thomas Hospitals in 1994 and obtained Membership of the Royal College of Physicians of London in 1997. He completed junior medical training in London and was subsequently awarded an Imperial Cancer Research Fund Clinical Research Fellowship that led to the completion of a PhD from Imperial College/Hammersmith Hospital (1998-2001). His research focused on gene transcriptional irregularities in cancer and gene therapy. Dr Shah completed Medical Oncology training at The Royal Marsden Hospital (2002-2006) before being appointed as a Consultant Medical Oncologist at the Kent Oncology Centre (2006-). He was awarded an ASCO Foundation Merit Award in 2005 for his work in a cancer known as carcinosarcoma.

Dr Shah specialises in thoracic and gastrointestinal malignancies and provides NHS clinics at Darent Valley, Maidstone and Tunbridge Wells Hospitals.

He is active in several local and national committees. At the time of writing he is the Chairman of the Lung Tumour Site Specific Group for the Kent Cancer Collaborative, Lead for Research at KOC, Member of the NCRI Lung Clinical Studies Group and Member of the Thoracic Surgery Clinical Reference Group.

He has a major interest in clinical research and acts as principal investigator on many trials in Kent. He was the UK Chief Investigator of the Lux LUNG 5 trial. He has published widely and is regularly invited to speak at local, national and international meetings.